Supira Medical

We are hiring! Want to be part of something special and help us bring an innovative and clinically differentiated #pVAD to market? We are hiring two key roles in our clinical organization as we grow our capabilities in this vital function. Senior Director, Clinical Operations https://lnkd.in/g_7BTMJA Senior Clinical Program Manager https://lnkd.in/gz92wQ9h

Thanks for joining us at #PCR2025!  The Supira Medical team had an excellent week meeting with physicians, collaborators, and colleagues to discuss how our next-generation system aims to transform the #pVAD market. Through #innovation, we intend to reduce risks, expand access to care, and support ease of use in high-risk PCI and cardiogenic shock. #medtech #cardiovascular #makingadifference 

Congratulations and thank you to Prof. Dr. Alexandre Abizaid on his presentation at #PCR2025 earlier today highlighting the 90-day results from our South America feasibility study. Dr. Abizaid reported the Supira System provided stable hemodynamic support throughout the HRPCI procedures and met primary safety and efficacy endpoints. With this strong signal of safety and efficacy, Supira looks forward to expanding our clinical program and building additional evidence to support this next-generation #pVAD technology. Don't forget to swing by Booth M27 to see the Supira System for yourself!  #innovation #medtech #cardiovascular #makingadifference 

We are looking forward to an exciting week at #EuroPCR2025! Don't miss Prof. Dr. Alexandre Abizaid present the 90-day results from our South America feasibility study next Thursday morning from 8:30-9:30 a.m. in Abstract & Case Corner B. And be sure to stop by Booth M27 to learn more about Supira's low-profile, high-flow #pVAD. #innovation #medtech #cardiovascular #makingadifference

Impressive! A huge thank you and congratulations to the Study Coordinators and PI's on the 30-day results of the SUPPORT I U.S. Early Feasibility Study presented on Friday during the late-breaking clinical science session at Society for Cardiovascular Angiography & Interventions. #pVAD #Innovation #MedTech #MakingADifference https://lnkd.in/g6SzGxnk

Join us at Society for Cardiovascular Angiography & Interventions! Don't miss Dr. David Kandzari's presentation of the 30-day results from Supira Medical's US SUPPORT I Early Feasibility Study (EFS) next Friday. We are thrilled for him to share these promising data as we continue to advance our clinical program and validate this next-generation system.  It's time to transform the #pVAD market and we are excited for what's next!  📊 Safety and Feasibility of the Supira System in High-Risk Percutaneous Coronary Interventions: 30-Day Results from the US SUPPORT I Early Feasibility Study (EFS) 🗓 Date: Friday, May 2, 2025 🕚 Time: 11:14 AM – 11:22 AM 📍 Location: Hall D: Case Exchange (435), Level 2 – Walter E. Washington Convention Center, Washington, D.C. 🎙 Speaker: Dr. David Kandzari, Director of Interventional Cardiology at Piedmont Heart Institute #pVAD #Innovation #MedTech #MakingADifference

Mark it. One week from today to learn more about Shifamed's portfolio, and of course our pVAD! See you in Riyadh. Cardiovascular Research Foundation

🚀 Big News! 🚀 We are thrilled to announce the successful closing of our Series E funding round, raising $120 million to accelerate our mission of transforming the pVAD market. This round was led by new investors Novo Holdings US and Qatar Investment Authority along with participation from two undisclosed strategics and existing investors including Cormorant Asset Management, LP, The Capital Partnership, 415 Capital, Amed Ventures, PA MedTech VC fund, and Unorthodox Ventures. This milestone wouldn’t be possible without our incredible team, supportive investors, and dedicated healthcare partners who believe in our mission. With this funding, we are scaling our clinical programs for both high-risk percutaneous coronary intervention (HRPCI) and cardiogenic shock (CS). #pVAD #Innovation #MedTech #MakingADifference 📖 Read the full press release here: https://lnkd.in/gZTHUPKw

🚀 Big News! 🚀 We are thrilled to announce the successful closing of our Series E funding round, raising $120 million to accelerate our mission of transforming the pVAD market. This round was led by new investors Novo Holdings US and Qatar Investment Authority along with participation from two undisclosed strategics and existing investors including Cormorant Asset Management, LP, The Capital Partnership, 415 Capital, Amed Ventures, PA MedTech VC fund, and Unorthodox Ventures. This milestone wouldn’t be possible without our incredible team, supportive investors, and dedicated healthcare partners who believe in our mission. With this funding, we are scaling our clinical programs for both high-risk percutaneous coronary intervention (HRPCI) and cardiogenic shock (CS). #pVAD #Innovation #MedTech #MakingADifference 📖 Read the full press release here: https://lnkd.in/gZTHUPKw

Dr. Tai Pham from UC Davis Health shared a challenging case presentation using the Supira pVAD during today's main session at the Cardiovascular Research Foundation's CTO Plus conference in NYC. We are excited to see continued progress and how new innovations can positively impact patient's lives!